【摘要】 目的:了解阿立哌唑治疗儿童少年期首发精神分裂症或分裂样精神病的临床疗效、安全性和不良反应。方法:将58例儿童精神分裂症患者随机分为阿立哌唑组30例和利培酮组28例进行8周治疗观察。采用阳性与阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)和锥体外系反应量表(RSESE)评定不良反应。结果:两药治疗儿童精神分裂症疗效相当。阿立哌唑组的EPS发生率9例(27%)明显低于利培酮组16例(57.1%)(P<0.05)。结论:阿立哌唑是一种安全有效的治疗首发儿童精神分裂症及分裂样精神病的药物。更多还原

【Abstract】 Objective :To explore the efficacy, safety and the main side effects of Aripiprazole in the treatment of first episode of schizophrenia or schizophreniform disorder in children and adolescences. Methods:58 schizophrenia children were divided into two groups, one was treated with Aripiprazole (n = 30) and the other was treated with Risperidone (n = 28) for 8 weeks, Both groups were administered with the positive and negative symptoms scale (PANSS), treatment emergent signs and symptoms (TESS) and rating scale for extra pyramidal side effects (RSESE) to evaluate their treatment efficacy and side reaction respectively. Results: The efficacies of both drugs in treatment of schizophrenia in children and adolescenees were similar, the occurrence of EPS in Aripiprazole group was 9 cases (27%). It was significantly lower than that of Risperidone group (16 cases, 57.1%) (P<0.05). Conclusions: Aripiprazole is a safe antipsychotic drug in the treatment of first episode schizophrenia in children and adolescences; it has good effect and good compliance.更多还原